Aardvark Therapeutics Analyst Price Targets

Aardvark Therapeutics Inc

AARDNASDAQ

$1.44

-0.07-4.64%

Últ. Act.: Oct 29, 9:28 AM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

Aardvark Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aardvark Therapeutics (AARD).

Price Target Range — 8 Quarters

Analyst Consensus — 11 Analysts

6Buy

4Hold

1Sell

Consensus RatingBuy# Analysts11Avg. Consensus PT$10Upside to Avg. PT+594.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 27, 2026	Jones Trading	Catherine Novack	PT Cut	Buy	$19→$10
Oct 26, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Neutral	$4→$2
Oct 19, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Neutral	$6→$4
Oct 12, 2026	BTIG	Jeet Mukherjee	Suspends	Neutral	—
Sep 24, 2026	RBC Capital	Brian Abrahams	Maintained	Sector Perform	$6
Jul 20, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Neutral	$6
May 15, 2026	B. Riley Securities	William Woods	PT Cut	Buy	$8→$7
May 15, 2026	BTIG	Jeet Mukherjee	Downgrade	Buy→Neutral	—
May 15, 2026	Morgan Stanley	Michael Ulz	Downgrade	Equal-Weight→Underweight	$7→$3
Mar 24, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$9
Mar 2, 2026	Oppenheimer	Leland Gershell	PT Cut	Outperform	$35→$21
Mar 2, 2026	BTIG	Jeet Mukherjee	PT Cut	Buy	$26→$9
Mar 2, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Downgrade	Buy→Neutral	—
Mar 2, 2026	Morgan Stanley	Michael Ulz	Downgrade	Overweight→Equal-Weight	$29→$7
Mar 2, 2026	Stifel	James Condulis	Downgrade	Buy→Hold	$24→$6
Mar 2, 2026	RBC Capital	Brian Abrahams	Downgrade	Outperform→Sector Perform	$18→$6
Feb 10, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$26
Feb 9, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$40
Dec 23, 2025	Oppenheimer	Leland Gershell	Initiate	Outperform	$35
Dec 12, 2025	William Blair	Andy Hsieh	Initiate	Outperform	—

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $2

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and lowers the price target from $4 to $2.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $4

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and lowers the price target from $6 to $4.

Benzinga Newsdesk

PRO
RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target

RBC Capital analyst Brian Abrahams reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Sector Perform and maintains $6 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and announces $6 price target.

Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7

B. Riley Securities analyst William Woods maintains Aardvark Therapeutics (NASDAQ:AARD) with a Buy and lowers the price target from $8 to $7.

Benzinga Newsdesk

This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Top Wall Street analysts changed outlook on top names. DA Davidson initiated coverage on EBC & UNTY with Buy ratings. See other analyst views.

Avi Kapoor

Aardvark Therapeutics Inc

Aardvark Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $2

PRO
HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $4

PRO
RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target

PRO
HC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price Target

PRO
B. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7

This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Aardvark Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $2

PRO
HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $4

PRO
RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target

PRO
HC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price Target

PRO
B. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7

This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

People Also Watch

People Also Watch

Aardvark Therapeutics Inc

Aardvark Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $2

PROHC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $4

PRORBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target

PROHC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price Target

PROB. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7

This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Aardvark Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $2

PROHC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $4

PRORBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target

PROHC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price Target

PROB. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7

This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $2

PRO
HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $4

PRO
RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target

PRO
HC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price Target

PRO
B. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7

PRO
HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $2

PRO
HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $4

PRO
RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target

PRO
HC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price Target

PRO
B. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7